×
About 5,120 results

ALLMedicine™ Schizoaffective Disorder Center

Research & Reviews  1,478 results

The relationship between cognitive clusters and telomere length in bipolar-schizophreni...
https://doi.org/10.1017/S0033291722002148
Psychological Medicine; Gurvich C, Thomas N et. al.

Aug 4th, 2022 - Schizophrenia and bipolar disorder are complex mental illnesses that are associated with cognitive deficits. There is considerable cognitive heterogeneity that exists within both disorders. Studies that cluster schizophrenia and bipolar patients i...

Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
https://clinicaltrials.gov/ct2/show/NCT05319080

Aug 4th, 2022 - The large majority of patients with schizophrenia (Sz) experience auditory verbal hallucinations (AVH) as a core feature of their disorder. Treatment-resistant auditory verbal hallucinations (AVH) affect a third of patients with schizophrenia and ...

Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A R...
https://doi.org/10.4088/JCP.21m14233
The Journal of Clinical Psychiatry; Levi L, Zamora D et. al.

Aug 4th, 2022 - Objective: Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. A confirmatory trial was conducted to test this hypothesis. Methods: This 16-week, multicenter, d...

Stimulating the Brain to Improve Self-Awareness
https://clinicaltrials.gov/ct2/show/NCT03370341

Aug 3rd, 2022 - Self-awareness is markedly impaired in severe mental illness including schizophrenia and schizoaffective disorder. This impairment spans awareness of symptoms as well as deficits in the estimation of abilities and capabilities, which we refer to a...

Is clinical insight a determinant factor of subjective recovery in persons living with ...
https://doi.org/10.1016/j.psychres.2022.114726
Psychiatry Research; Galliot G, Sanchez-Rodriguez R et. al.

Aug 2nd, 2022 - Good clinical insight is predictive of clinical recovery in schizophrenia (i.e. symptomatic remission and functional improvement). However, the recent subjective recovery paradigm (i.e. the self-identity reconstruction process with and beyond psyc...

see more →

Drugs  52 results see all →

Clinicaltrials.gov  336 results

Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
https://clinicaltrials.gov/ct2/show/NCT05319080

Aug 4th, 2022 - The large majority of patients with schizophrenia (Sz) experience auditory verbal hallucinations (AVH) as a core feature of their disorder. Treatment-resistant auditory verbal hallucinations (AVH) affect a third of patients with schizophrenia and ...

Stimulating the Brain to Improve Self-Awareness
https://clinicaltrials.gov/ct2/show/NCT03370341

Aug 3rd, 2022 - Self-awareness is markedly impaired in severe mental illness including schizophrenia and schizoaffective disorder. This impairment spans awareness of symptoms as well as deficits in the estimation of abilities and capabilities, which we refer to a...

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms
https://clinicaltrials.gov/ct2/show/NCT03669640

Jul 27th, 2022 - This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules in Subjects With Schizophrenia, Schizoaffective Disorder
https://clinicaltrials.gov/ct2/show/NCT04567524

Jul 20th, 2022 - LYN-005-C-004 is a blinded, multiple-dose, randomized, parallel group, safety, tolerability and PK study of LYN-005 in subjects with a primary diagnosis of schizophrenia or schizoaffective disorder in general good health. Eligible subjects must be...

A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
https://clinicaltrials.gov/ct2/show/NCT04512066

Jul 15th, 2022 - This study will investigate the efficacy and safety of RO6889450 as monotherapy in participants experiencing an acute exacerbation of symptoms of schizophrenia or schizoaffective disorder.

see more →

News  180 results

Advance Directives for Psychiatric Care Reduce Compulsory Admissions
https://www.medscape.com/viewarticle/975938

Jun 21st, 2022 - Providing peer or community health workers to help psychiatric patients with complete psychiatric advance directives (PAD) to govern care in advance of a mental health crisis is associated with a significant reduction in compulsory hospital admiss...

New Tool Cuts CVD Risk in Patients With Serious Mental Illness
https://www.medscape.com/viewarticle/970576

Mar 18th, 2022 - A clinical decision support (CDS) system that can be implemented in primary care reduces cardiovascular (CV) risk factors common in patients with serious mental illness (SMI), new research suggests. Investigators assessed more than 70 primary care...

Pregnant Mentally-Ill Woman Can Have C-Section Against Her Will, Judge Rules
https://www.medscape.com/viewarticle/970121

Mar 11th, 2022 - Doctors can perform a caesarean section against the will of a diabetic woman in her late 20s who has mental health difficulties, a judge has ruled. The heavily pregnant woman has been diagnosed with schizoaffective disorder, and is detained under ...

Greater Lifetime Heart Risk Seen in Bipolar, Schizophrenia
https://www.medpagetoday.com/cardiology/prevention/97584

Mar 9th, 2022 - Primary care patients with serious mental illness are more likely to experience heart ailments too, a new study suggested. After adjusting for various factors, individuals ages 40 to 75 with bipolar disorder, schizophrenia, or schizoaffective diso...

Fast Five Quiz: Tardive Dyskinesia Differential Diagnosis
https://www.medscape.com/viewarticle/923959

Jan 18th, 2022 - Tardive dyskinesia (TD) presents as involuntary movements of the tongue, lips, jaw, face, trunk, and extremities that occur in patients treated with long-term dopaminergic antagonist medications. TD is most common in patients with schizophrenia, s...

see more →

Patient Education  2 results see all →